Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast

American Journal of Surgical Pathology

Volumn 34, Issue 10, 2010, Pages 1472-1479

  Rakha, Emad A ^a   Patel, Arjun ^a   Powe, Des G ^a   Benhasouna, Ahmed ^a   Green, Andrew R ^a   Lambros, Maryou B ^b   Reis Filho, Jorge S ^b   Ellis, Ian O ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

breast cancer; catenins; E cadherin; immunohistochemistry; invasive lobular carcinoma

Indexed keywords

CADHERIN; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER INVASION; FEMALE; HUMAN; LUNG CARCINOMA; LYMPH NODE; MENOPAUSE; METABOLISM; MIDDLE AGED; PATHOLOGY;

BREAST NEOPLASMS; CADHERINS; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPH NODES; MENOPAUSE; MIDDLE AGED; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957898444     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181f01916     Document Type: Article

References (59)

1. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340-350.
2. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem. 1996;61:514-523.
3. Acs G, Lawton TJ, Rebbeck TR, et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001;115:85-98.
4. Asgeirsson KS, Jo JG, Tryggvadottir L, et al. Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. Eur J Cancer. 2000;36:1098-1106.
5. Batlle E, Sancho E, Franci C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2:84-89.
6. Berx G, Cleton-Jansen AM, Nollet F, et al. E-cadherin is a tumour/ invasion suppressor gene mutated in human lobular breast cancers. Embo J. 1995;14:6107-6115.
7. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13:1919-1925.
8. Berx G, Becker KF, Hofler H, et al. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998;12:226-237.
9. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994;1198:11-26.
10. Bratthauer GL, Moinfar F, Stamatakos MD, et al. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Hum Pathol. 2002;33:620-627.
11. Bukholm IK, Nesland JM, Karesen R, et al. Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch. 1997;431:317-321.
12. Chan JK, Wong CS. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol. 2001;8:165-172.
13. Cowley GP, Smith ME. Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas. Int J Cancer. 1995;60:325-329.
14. Da Silva L, Parry S, Reid L, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol. 2008;32:773-783.
15. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183:404-411.
16. Derksen PW, Liu X, Saridin F, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10:437-449.
17. Dillon DA, D'Aquila T, Reynolds AB, et al. The expression of p120ctn protein in breast cancer is independent of alpha-and beta-catenin and E-cadherin. Am J Pathol. 1998;152:75-82.
18. Droufakou S, Deshmane V, Roylance R, et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 2001;92:404-408.
19. Ellis IO, Galea M, Broughton N, et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992;20:479-489.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
21. Elston CW, Ellis IO. The Breast. Edinburgh: Churchill Livingstone; 1998:239-249.
22. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993;142:987-993.
23. Goldstein NS. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases? Am J Clin Pathol. 2002;118:425-434.
24. Goldstein NS, Bassi D, Watts JC, et al. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol. 2001; 115:534-542.
25. Goldstein NS, Kestin LL, Vicini FA. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer. 2001;92:738-747.
26. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55:5195-5199.
27. Handschuh G, Candidus S, Luber B, et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene. 1999;18: 4301-4312.
28. Huber O, Bierkamp C, Kemler R. Cadherins and catenins in development. Curr Opin Cell Biol. 1996;8:685-691.
29. Huber O, Krohn M, Kemler R. A specific domain in alpha-catenin mediates binding to beta-catenin or plakoglobin. J Cell Sci. 1997; 110:1759-1765.
30. Huiping C, Sigurgeirsdottir JR, Jonasson JG, et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer. 1999;81:1103-1110.
31. Jacobs TW, Pliss N, Kouria G, et al. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol. 2001;25:229-236.
32. Jacquemier J, Eisinger F, Nogues C, et al. Histological type and syncytial growth pattern affect E-cadherin expression in a multi-factorial analysis of a combined panel of sporadic and BRCA1-associated breast cancers. Int J Cancer. 1999;83:45-49.
33. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337-342.
34. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet. 1993;9:317-321.
35. Korkola JE, DeVries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003;63:7167-7175.
36. Lei H, Sjoberg-Margolin S, Salahshor S, et al. CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer. 2002;98:199-204.
37. Mahler-Araujo B, Savage K, Parry S, et al. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol. 2008;61: 615-620.
38. Mastracci TL, Tjan S, Bane AL, et al. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol. 2005;18:741-751.
39. Moll R, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993;143:1731-1742.
40. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology. 2002;40: 536-546.
41. Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53:1696-1701.
42. Paredes J, Correia AL, Ribeiro AS, et al. Breast carcinomas that co-express E-and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J Clin Pathol. 2008;61:856-862.
43. Pierceall WE, Woodard AS, Morrow JS, et al. Frequent alterations in E-cadherin and alpha-and beta-catenin expression in human breast cancer cell lines. Oncogene. 1995;11:1319-1326.
44. Rakha EA, Abd El Rehim D, Pinder SE, et al. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46:685-693.
45. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495-506.
46. Rakha EA, El-Sayed ME, Menon S, et al. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2008;111:121-127.
47. Reis-Filho JS, Cancela Paredes J, Milanezi F, et al. Clinicopatho-logic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer. 2002;94:2114-2115; discussion 2115-2116.
48. Rieger-Christ KM, Pezza JA, Dugan JM, et al. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol Pathol. 2001;54:91-97.
49. Sarrio D, Perez-Mies B, Hardisson D, et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene. 2004;23:3272-3283.
50. Shibata T, Kokubu A, Sekine S, et al. Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol. 2004;164:2269-2278.
51. Sommers CL, Thompson EW, Torri JA, et al. Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Differ. 1991;2:365-372.
52. Strathdee G. Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin Cancer Biol. 2002;12:373-379.
53. Tavassoli F, Devilee P. World Health Organization Classification of Tumours. Lyon: IARCPress; 2003:23-26.
54. Vleminckx K, Vakaet L Jr, Mareel M, et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66:107-119.
55. Vos CB, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76:1131-1133. (Pubitemid 27448007)
56. Wahed A, Connelly J, Reese T. E-cadherin expression in pleo-morphic lobular carcinoma: an aid to differentiation from ductal carcinoma. Ann Diagn Pathol. 2002;6:349-351.
57. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009; 6:718-730.
58. Weigelt B, Geyer FC, Natrajan R, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade-and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol. 2010;220:45-57.
59. Yoshiura K, Kanai Y, Ochiai A, et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci \USA. 1995;92:7416-7419.